NIOSHTIC-2 Publications Search
Defective release of growth hormone in parkinsonism improved by levodopa.
Mena-I; Cotzias-GC; Brown-FC; Papavasiliou-PS; Miller-ST
N Engl J Med 1973 Feb; 288(6):320-321
Determinations were made of serum growth hormone levels every 30 minutes for two separate 24 hour periods in patients with Parkinsonism, using a radioimmunoassay method. The basal levels in three patients with untreated Parkinsonism ranged from 2 to 5 nanograms per milliliter of serum, and were similar to those reported for normal subjects. The records from all runs were flat, except for a total of five short lived rises averaging 7 nanograms above the basal levels. Runs with patients being treated with 500 to 700 milligrams of levodopa six times a day were similar to records obtained from normal individuals. The first morning dose of levodopa increased the levels of growth hormone 10 to 50 nanograms above the basal levels. Subsequent doses evoked smaller rises. The duration and numbers were often similar to those reported for normal subjects. The sum of all measurements conducted each 30 minutes for 8 hours indicated for the untreated versus the treated patients a mean of 67 versus 117 nanograms per 8 hours. The sum of all measurements remaining after subtracting the basal levels to reflect only the rises showed, respectively, 7 versus 62 nanograms per 8 hours for untreated versus treated patients. The authors suggest a defective output of growth hormone exists in patients with Parkinsonism, which levodopa appeared to correct.
Neurotoxic-effects; Hormone-activity; Medical-treatment; Nervous-system-disorders; Circadian-rhythms
Nuclear Medicine Pan American Hlth Organization 525 23Rd Street, N W Washington, D C 20037
Issue of Publication
Neurotoxic Disorders; Neurotoxic-effects
New England Journal of Medicine
Pan American Health Organization, Washington, Dist of Col
Page last reviewed: September 2, 2020
Content source: National Institute for Occupational Safety and Health Education and Information Division